Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds
Standard combination protocol The most commonly employed stack uses moderate doses of both peptides administered daily or near-daily for defined treatment cycles
B12 is water-soluble, and its generally safe even at very high doses
Candidates may include those seeking adjunctive support for recovery after injury, surgery, or chronic inflammation, but it should never replace conventional medical treatment or rehabilitation protocols
Format Lyophilized Peptide Purity High-Purity Tested Vial sizes Available in Multiple Strengths Storage Refrigerated Storage Recommended Reconstitution Bacteriostatic Water Compatible COA Certificate of Analysis Available Research Domains BPC-157 Supports Tissue Repair